Podcasts about multidisciplinary

Welcome to Art is Awesome, the show where we talk with an artist or art worker with a connection to the San Francisco Bay Area. About Artist Amy Trachtenberg:Amy Trachtenberg is a multidisciplinary artist whose work includes painting, collage, sculpture, installation, poetry and public projects. Diverse in their scale and material sources, hybrid paintings and objects exist between fiction and abstraction. By bringing what exists in the world into the work, awareness is aroused by the qualities of color, tactility, and an appetite for examining the remains of material culture. Structures woven together are built on memory and forgetfulness with relationships between architecture, the body and everyday objects.Visit Amy's Website: AmyTrachtenberg.comFollow Amy on Instagram: @AmyClaireTFor more on Amy's Exhibit "Abstract Objects of Devotion" CLICK HERE--About Podcast Host Emily Wilson:Emily a writer in San Francisco, with work in outlets including Hyperallergic, Artforum, 48 Hills, the Daily Beast, California Magazine, Latino USA, and Women's Media Center. She often writes about the arts. For years, she taught adults getting their high school diplomas at City College of San Francisco.Follow Emily on Instagram: @PureEWilFollow Art Is Awesome on Instagram: @ArtIsAwesome_Podcast--CREDITS:Art Is Awesome is Hosted, Created & Executive Produced by Emily Wilson. Theme Music "Loopster" Courtesy of Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 4.0 LicenseThe Podcast is Co-Produced, Developed & Edited by Charlene Goto of @GoToProductions. For more info, visit Go-ToProductions.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The first thing we learn on Episode 283 of The Unique CPA is that Randy has real trouble saying the word "multidisciplinary." Once we've worked that out, we learn that his guest Mike Payne built his career on a bet that most professionals avoid: pairing a law degree with a CPA license instead of picking a lane. That combination became the foundation of BOSS Advisors, a firm he grew to $2 million before recognizing the ceiling of his own skillset. Rather than force growth he wasn't suited to drive, Payne sold the firm to Haga Kommer, a Midwest-based multidisciplinary group with plans for an employee stock ownership structure. Now serving as Chief Growth Officer, he's applying the same generalist philosophy that built his practice, and he argues that AI makes broad issue-spotting more valuable and accessible than narrow specialization, since professionals who can flag a problem can always bring in the right expert to solve it. Mike unpacks the mechanics of merging a law-and-accounting practice, the ethics rules that shaped it, and what business owners should weigh before selling to a larger platform. Get the full show notes and more resources at TheUniqueCPA.com

Cardiovascular disease is a major threat to maternal health during pregnancy and the peripartum period, particularly for women with preexisting heart conditions. A UC San Diego cardiologist describes the development of a multidisciplinary cardio-obstetrics initiative designed to coordinate care for patients with congenital heart disease, heart failure, arrhythmias and coronary artery disease. The program brings cardiology and maternal-fetal medicine together with other specialties to establish consistent protocols, improve maternal and fetal outcomes, advance research and train future clinicians. As more people born with congenital heart disease survive into adulthood and consider pregnancy, the need for this specialized care continues to grow. Longitudinal surveillance is also helping researchers study outcomes and identify opportunities for better monitoring. Coordinated cardio-obstetrics care can help manage complex cardiovascular risks throughout pregnancy and delivery. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 41641]

Cardiovascular disease is a major threat to maternal health during pregnancy and the peripartum period, particularly for women with preexisting heart conditions. A UC San Diego cardiologist describes the development of a multidisciplinary cardio-obstetrics initiative designed to coordinate care for patients with congenital heart disease, heart failure, arrhythmias and coronary artery disease. The program brings cardiology and maternal-fetal medicine together with other specialties to establish consistent protocols, improve maternal and fetal outcomes, advance research and train future clinicians. As more people born with congenital heart disease survive into adulthood and consider pregnancy, the need for this specialized care continues to grow. Longitudinal surveillance is also helping researchers study outcomes and identify opportunities for better monitoring. Coordinated cardio-obstetrics care can help manage complex cardiovascular risks throughout pregnancy and delivery. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 41641]

Cardiovascular disease is a major threat to maternal health during pregnancy and the peripartum period, particularly for women with preexisting heart conditions. A UC San Diego cardiologist describes the development of a multidisciplinary cardio-obstetrics initiative designed to coordinate care for patients with congenital heart disease, heart failure, arrhythmias and coronary artery disease. The program brings cardiology and maternal-fetal medicine together with other specialties to establish consistent protocols, improve maternal and fetal outcomes, advance research and train future clinicians. As more people born with congenital heart disease survive into adulthood and consider pregnancy, the need for this specialized care continues to grow. Longitudinal surveillance is also helping researchers study outcomes and identify opportunities for better monitoring. Coordinated cardio-obstetrics care can help manage complex cardiovascular risks throughout pregnancy and delivery. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 41641]

Cardiovascular disease is a major threat to maternal health during pregnancy and the peripartum period, particularly for women with preexisting heart conditions. A UC San Diego cardiologist describes the development of a multidisciplinary cardio-obstetrics initiative designed to coordinate care for patients with congenital heart disease, heart failure, arrhythmias and coronary artery disease. The program brings cardiology and maternal-fetal medicine together with other specialties to establish consistent protocols, improve maternal and fetal outcomes, advance research and train future clinicians. As more people born with congenital heart disease survive into adulthood and consider pregnancy, the need for this specialized care continues to grow. Longitudinal surveillance is also helping researchers study outcomes and identify opportunities for better monitoring. Coordinated cardio-obstetrics care can help manage complex cardiovascular risks throughout pregnancy and delivery. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 41641]

Cardiovascular disease is a major threat to maternal health during pregnancy and the peripartum period, particularly for women with preexisting heart conditions. A UC San Diego cardiologist describes the development of a multidisciplinary cardio-obstetrics initiative designed to coordinate care for patients with congenital heart disease, heart failure, arrhythmias and coronary artery disease. The program brings cardiology and maternal-fetal medicine together with other specialties to establish consistent protocols, improve maternal and fetal outcomes, advance research and train future clinicians. As more people born with congenital heart disease survive into adulthood and consider pregnancy, the need for this specialized care continues to grow. Longitudinal surveillance is also helping researchers study outcomes and identify opportunities for better monitoring. Coordinated cardio-obstetrics care can help manage complex cardiovascular risks throughout pregnancy and delivery. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 41641]

Cardiovascular disease is a major threat to maternal health during pregnancy and the peripartum period, particularly for women with preexisting heart conditions. A UC San Diego cardiologist describes the development of a multidisciplinary cardio-obstetrics initiative designed to coordinate care for patients with congenital heart disease, heart failure, arrhythmias and coronary artery disease. The program brings cardiology and maternal-fetal medicine together with other specialties to establish consistent protocols, improve maternal and fetal outcomes, advance research and train future clinicians. As more people born with congenital heart disease survive into adulthood and consider pregnancy, the need for this specialized care continues to grow. Longitudinal surveillance is also helping researchers study outcomes and identify opportunities for better monitoring. Coordinated cardio-obstetrics care can help manage complex cardiovascular risks throughout pregnancy and delivery. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 41641]

Cardiovascular disease is a major threat to maternal health during pregnancy and the peripartum period, particularly for women with preexisting heart conditions. A UC San Diego cardiologist describes the development of a multidisciplinary cardio-obstetrics initiative designed to coordinate care for patients with congenital heart disease, heart failure, arrhythmias and coronary artery disease. The program brings cardiology and maternal-fetal medicine together with other specialties to establish consistent protocols, improve maternal and fetal outcomes, advance research and train future clinicians. As more people born with congenital heart disease survive into adulthood and consider pregnancy, the need for this specialized care continues to grow. Longitudinal surveillance is also helping researchers study outcomes and identify opportunities for better monitoring. Coordinated cardio-obstetrics care can help manage complex cardiovascular risks throughout pregnancy and delivery. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 41641]

Cardiovascular disease is a major threat to maternal health during pregnancy and the peripartum period, particularly for women with preexisting heart conditions. A UC San Diego cardiologist describes the development of a multidisciplinary cardio-obstetrics initiative designed to coordinate care for patients with congenital heart disease, heart failure, arrhythmias and coronary artery disease. The program brings cardiology and maternal-fetal medicine together with other specialties to establish consistent protocols, improve maternal and fetal outcomes, advance research and train future clinicians. As more people born with congenital heart disease survive into adulthood and consider pregnancy, the need for this specialized care continues to grow. Longitudinal surveillance is also helping researchers study outcomes and identify opportunities for better monitoring. Coordinated cardio-obstetrics care can help manage complex cardiovascular risks throughout pregnancy and delivery. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 41641]

AUA2026: Advanced Prostate Cancer in the News 2026: A Case-Based Multidisciplinary Update CME Available: https://cme.auanet.org/URL/26DC010ONL LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral androgen blockers/inhibitors. Furthermore, to recognize high volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team. In addition, to recognize and employ molecular genetic testing to help dictate proper therapy. 2. Non Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): Diagnose M0CRPC and to be able to educate patients about using novel oral androgen receptor targeted agents added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three novel oral agents and to educate patients about side-effects and toxicities. Finally, to understand the pros and cons of PSMA PET scan imaging in further staging in this disease state. 3. Metastatic Castrate Resistant Prostate Cancer (M1 CRPC): Define and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and to be able to educate their patients on treatment options and be able to participate in a multidisciplinary team caring for men with this disease state of far advanced prostate cancer. 4. Identify that advanced prostate cancer is a complex group of disease states with an ever changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients. 5. Describe the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, Immune Checkpoint agents and novel AR targeted agents emerging in 2026 and beyond. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astellas Lantheus Medical Imaging Novartis Pharmaceuticals Corporation Pfizer, Inc

Please visit answersincme.com/AQE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nirmala Gonsalves, MD, AGAF, FACG. In this activity, an expert in esophageal gastroenterology, discusses strategies for pharmacological treatment of eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Specify the current guideline recommendations for the pharmacologic treatment of eosinophilic esophagitis (EoE); Formulate personalized strategies to use approved pharmacologic options during initiation and maintenance phases of EoE management; and Apply multidisciplinary strategies to optimize long-term management of patients with EoE using approved pharmacologic treatments.

Multidisciplinary artist, Christopher Webb discusses the early influence his grandmother had on him when she introduced him to oil painting at age three. Our conversation explores the intersection of art, business, and collaboration as Christopher reflects on significant projects, including selling artwork on the waterfront and a pivotal show with his friend Lennett Anderson. While acknowledging past achievements, Webb expresses excitement about his current work, future projects and lack of a traditional retirement plan. Christopher finds inspiration in his family's immigration story – making works that explore themes of identity, belonging, and the sacrifices made by his ancestors. He also reflects on the importance of preserving family traditions and recipes, as they evolve and adapt over time. The Creative Nova Scotia Awards are presented by Arts Nova Scotia and the Creative Nova Scotia Leadership Council to celebrate artistic excellence across Mi'kma'ki. Award categories are as follows: Creative Community Impact Prix Grand-Pré Established Artist Emerging Artist Black Artist Indigenous Artist The Portia White Prize Collectively, the awards are worth $75,000! Visit artsns.ca for more information. This series would not be possible without the fantastic production work of Heist and Keke Beatz.

Are there critical concussion symptom profiles that you are missing in your clinical practice? In this episode, host Dr. Phil Plisky, PT, DSc, ATC, CSCS, sits down with Dr. Mary Ann Roelke, OTD, OTR, a distinguished expert with over 35 years of experience in neurologic rehabilitation, to challenge the way we approach postconcussion care. Together, they unpack why concussions must be treated as complex neurological injuries rather than standard musculoskeletal setbacks, detailing how global life impairments often slip through the cracks. You will discover how simple clinical shifts—such as testing positional blood pressure and using specific symptom screening clusters—can dramatically reshape your treatment trajectories, while learning to effectively leverage multidisciplinary “superpowers” and actionable pacing rules to confidently guide your patients back to the activities that bring them joy.Learning OutcomesAnalyze the evidence around concussion rehabilitation identification, education, and multidisciplinary referralApply evidence-based, practical strategies to actionably address progressive return to meaningful activities and symptom management after a concussionSolve patient case scenarios involving complex concussion clinical profiles and coordinated multidisciplinary careTimestamps(00:00:00) Welcome(00:00:05) Introduction to concussion rehabilitation(00:01:32) Dr. Roelke's background and expertise(00:02:10) Why concussion rehab is unique(00:03:44) Understanding the complexity of brain injury(00:05:22) Addressing persisting symptoms(00:07:59) Blood pressure testing and autonomic nervous system(00:10:16) Cognitive and emotional impact(00:12:46) Research and symptom profiles(00:15:53) Education, identification, and referral(00:18:45) Activity pacing and safe movement(00:19:50) Multidisciplinary referrals(00:25:13) Rehabilitation and practical clinic application(00:29:46) Case study: complex concussion management(00:34:16) Interventions and strategies(00:38:12) Key takeaways for clinicians(00:38:50) Current projects and further learning(00:40:25) Staying connected and resourcesRehab and Performance Lab is brought to you by Medbridge. If you'd like to earn continuing education credit for listening to this episode and access bonus takeaway handouts, log in to your Medbridge account and navigate to the course where you'll find accreditation details. If applicable, complete the post-course assessment and survey to be eligible for credit. The takeaway handout on Medbridge gives you the key points mentioned in this episode, along with additional resources you can implement into your practice right away.To hear more episodes of Rehab and Performance Lab, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.medbridge.com/rehab-and-performance-lab⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠If you'd like to subscribe to Medbridge, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.medbridge.com/pricing/

CardioNerds (Dr. Apoorva Gangavelli, Dr. Cory Sejo, and Dr. Joseph Kassab), discuss tricuspid regurgitation evaluation and management with Dr. Sunil Mankad. This episode was produced as part of the CardioNerds Academy curriculum by House Einthoven under the guidance of House Chief, Dr. Apoorva Gangavelli and Academy Program Director, Dr. Gurleen Kaur. A matching review article will be published in US Cardiology Review, the official journal of CardioNerds. This discussion was planned in collaboration with the Mayo Clinic Cardiovascular Board Review Course.  Audio editing by CardioNerds intern Emma Winakur. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Key Points: Tricuspid regurgitation is common and associated with increased mortality at every stage, regardless of etiology. Outcomes are worse with worsening severity, so accurate grading is critical. Etiology is critical to guide treatment decisions. Etiology includes primary vs secondary (atrial or ventricular) vs CIED-related TR. 3D echocardiography can be very helpful in determining TR etiology, especially in CIED-related TR. Diuresis with the goal of euvolemia is step one. Additionally, underlying contributory conditions (eg. pulmonary HTN, HFrEF, atrial fibrillation) should be addressed, if appropriate, and then TR severity reassessed. The choice between T-TEER and TTVR hinges on anatomy, RV function, pulmonary hypertension, and the ability to tolerate anticoagulation. T-TEER is generally first line in atrial functional TR with appropriate anatomy, in patients with poor RV function who cannot tolerate a sudden increase in RV afterload, or in patients who cannot tolerate the necessary anticoagulation with TTVR. TTVR is preferred with wide coaptation gaps and CIED-related TR. This is a team sport. Multidisciplinary discussions utilizing imaging (TTE/TEE, CT), risk scores (TRI-SCORE or TRIO), patient preference, and prior institutional experience are essential for the effective treatment of severe TR. Notes: What is the clinical importance of tricuspid regurgitation? TR is very common with approximately 4% of people over 75 having moderate or greater severity. TR (even mild) is associated with increased mortality. Those outcomes worsen as the TR severity worsens, and this phenomenon is independent of the mechanism of regurgitation. What is unique about the tricuspid valve compared to the other cardiac valves? It is at an anterior location which allows it to be imaged well with transthoracic echocardiography It is the largest valve and composed generally of 3 leaflets (but very often can have 4+ leaflets). Importantly, the RV is compliant and changes size and shape readily based on loading conditions. The TV annulus similarly changes size and shape based on hemodynamic conditions such as preload. What is a good framework for approaching the causes of tricuspid regurgitation? Determine the presence and define the severity of TR. Using TTE, we want to measure the right atrial size, the RV size, and any other concomitant valvular lesions.  Use TTE (2D and 3D) to characterize leaflet anatomy and characteristics. Subtypes of TR mechanisms (many times etiology is mixed). Primary: primary leaflet abnormality, occurs in ~10% of cases. Look for prolapse, flail, endocarditis, etc. Secondary/functional: leaflets normal but surrounding structures are abnormal. Atrial: RA and tricuspid annular dilation but normal RV size/shape, and can be related to arrhythmias like atrial fibrillation. Ventricular: RV dilated and/or dysfunctional with leaflet tethering. Can be related to pulmonary hypertension or primary RV disease. Cardiac implantable electronic device (CIED): Related to device (usually pacemakers or ICD) interaction with TV leaflets. Includes perforation, entanglement in subvalvular apparatus, impingement, etc. 3D TTE particularly helpful to evaluate How do we grade TR severity? It is very important to grade the severity of TR, and this is generally done with echocardiography. There are both quantitative and qualitative methods which use Doppler and various equations to estimate TR severity. Current recommendations have expanded TR severity beyond mild/moderate/severe to include “massive” and “torrential” categories. The most important parameters measured/calculated are vena contracta width, regurgitant volume, regurgitant fraction, and effective regurgitant orifice area. Helpful qualitative metrics include hepatic venous flow reversal. When should additional studies beyond transthoracic echocardiography, such as transesophageal echocardiography (TEE), cardiac computed tomography (CT), and cardiac magnetic resonance imaging (MRI) be pursued? TEE is particularly helpful if TTE views are poor. Since TEE is used during transcatheter intervention, a pre-procedure TEE to define anatomy, determine procedure candidacy, and plan for the procedure is critical.  CT is also helpful for procedure planning and has particular strengths in defining annulus size and geometry. A CT is required prior to transcatheter tricuspid valve replacement (TTVR). MRI is helpful for measuring RV volumes and function, but is not generally used to assess TR severity.  What is the approach to the treatment for severe tricuspid regurgitation? The first step is to try to determine the etiology. For secondary TR, treating the underlying condition is indicated. For example, pulmonary vasodilators for pulmonary HTN or guideline therapy for heart failure with reduced ejection fraction. Diuretics are the mainstay for treatment, with the goal to obtain euvolemia. This may require inpatient admission to optimize volume status and medication regimen. Once reversible etiologies are addressed, if the patient is still symptomatic from TR, additional therapies can be considered. What is the role of right heart catheterizations (RHC) in patients with severe TR? RHC is very helpful for many reasons. We use it in TR to help determine volume status, cardiac output, and RV function. Additionally, identifying and characterizing pulmonary hypertension (with pulmonary artery pressures and calculating pulmonary vascular resistance) is an important factor when choosing future therapies.  With severe tricuspid regurgitation, when should we refer for intervention (either with surgery or transcatheter repair or replacement)? Once reversible etiologies are addressed and euvolemia has been achieved, if the patient is still symptomatic from TR despite aggressive medical optimization, additional therapies can be considered. Once euvolemic, a repeat TTE should be ordered to reassess the severity of the TR. Use calculators (for example, either the TRI-SCORE or TRIO score) to predict operative mortality for isolated TR surgery. What are our transcatheter treatment options in severe tricuspid regurgitation, and how do we choose between them? The primary approved transcatheter treatment options for severe TR include transcatheter tricuspid edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR), of which the Edwards EVOQUE valve is the only one currently approved by the FDA. There are other TTVR device under investigation. These decisions should be made with a multi-disciplinary team including representation from cardiac imaging, interventional cardiology, and cardiothoracic surgery. Factors that go into the decision between T-TEER and TTVR include anatomy (annulus width, coaptation gap, leaflet length), RV reserve, pulmonary hypertension presence, ability to tolerate anticoagulation, patient preference, and institutional experience.  T-TEER is generally the first line with atrial functional and suitable anatomy. It is successful at reducing TR but does not generally eliminate it.  TTVR with EVOQUE is preferred in certain anatomic considerations like a large coaptation gap or when there is CIED-related TR (as this was excluded in T-TEER trials). Patients must be suitable for anticoagulation to receive TTVR as there is risk of leaflet thrombosis without it. If moderate/severe pulmonary hypertension is present, or there is poor RV function, TTVR may be avoided as the sudden elimination of TR causes a sudden increase in RV afterload which may not be tolerated. What is the role in advanced metrics for evaluating RV function? Advanced metrics like RV/PA coupling are under investigation but have not made it into the guidelines. The clinical utility is not yet known.  Assessing the RV function is important as stated above. Dr. Mankad prefers using 3D TTE to calculate an RVEF, or tracking RV longitudinal free wall strain. If you do encounter CIED-related TR, how do you treat it? Evaluate with TTE or TEE. 3D is very helpful to identify relative anatomy and leaflet-device interactions. There is no clear consensus about treatment if CIED-related TR is the primary mechanism of severe TR. If recently implanted, repositioning may be a valid option, but requires discussions with multiple teams including electrophysiology, advanced cardiac imaging, CT surgery, and interventional cardiology. References O’Gara PT, Lindenfeld J, Hahn RT, et al. 10 Issues for the Clinician in Tricuspid Regurgitation Evaluation and Management: 2025 ACC Expert Consensus Decision Pathway. J Am Coll Cardiol. 2025;S0735-1097(25)07047-0. O’Gara PT, Little SH, Badhwar V, et al. Operator and Institutional Recommendations and Requirements for Tricuspid Interventions: 2026 ACC/AHA/ASE/HRS/STS Expert Consensus Systems of Care Document. J Am Coll Cardiol. 2026;S0735-1097(26)05481-1. Hahn RT. Tricuspid Regurgitation. N Engl J Med. 2023;388(20):1876-1891. Davidson LJ, Tang GHL, Ho EC, et al. The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association. Circulation. 2024;149(22):e1223-e1238.

Please visit answersincme.com/GFY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vishal A. Patel, MD; and Jonathan S. Zager, MD, FACS, FSSO. In this activity, experts in cutaneous oncology discuss the evolving role of gene expression profiling (GEP) tests in refining risk assessment and supporting individualized, multidisciplinary management strategies for patients with melanoma. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using GEP tests to stratify the risk of disease progression in patients with cutaneous melanoma; Review the clinical evidence, including guideline-supported data, for GEP tests to stratify disease progression risk in patients with cutaneous melanoma; Formulate multidisciplinary strategies for incorporating the results of GEP tests into risk-based management of patients with cutaneous melanoma; and Outline patient-centered approaches to integrating GEP tests into the management of patients with cutaneous melanoma at risk of metastasis.

Please visit answersincme.com/GFY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vishal A. Patel, MD; and Jonathan S. Zager, MD, FACS, FSSO. In this activity, experts in cutaneous oncology discuss the evolving role of gene expression profiling (GEP) tests in refining risk assessment and supporting individualized, multidisciplinary management strategies for patients with melanoma. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using GEP tests to stratify the risk of disease progression in patients with cutaneous melanoma; Review the clinical evidence, including guideline-supported data, for GEP tests to stratify disease progression risk in patients with cutaneous melanoma; Formulate multidisciplinary strategies for incorporating the results of GEP tests into risk-based management of patients with cutaneous melanoma; and Outline patient-centered approaches to integrating GEP tests into the management of patients with cutaneous melanoma at risk of metastasis.

Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive disease that can cause chronic pain, joint dysfunction, reduced mobility, and significant impacts on quality of life, particularly in patients with diffuse disease. In this expert discussion, Dr William Tap and Dr Emanuela Palmerini explore the evolving management of TGCT, including the biologic role of the CSF1/CSF1R pathway, challenges in diagnosis and disease monitoring, and the importance of multidisciplinary, patient-centered care. They also discuss the growing role of CSF1R-targeted therapies, treatment selection, toxicity management, drug holidays, and practical approaches to optimizing long-term outcomes for patients living with TGCT.  Topics Covered Understanding localized vs diffuse TGCT Biology of the CSF1/CSF1R pathway Diagnostic approaches and the role of MRI and biopsy Multidisciplinary care and shared decision-making Impact of TGCT on function, mobility, and quality of life Current and emerging CSF1R-targeted therapies Pexidartinib and vimseltinib: clinical considerations and toxicity management Response assessment beyond imaging Drug holidays, retreatment strategies, and long-term follow-up Future directions in TGCT research and treatment Faculty William Tap, MD Emanuela Palmerini, MD, PhD Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In episode 172, “Spinal Muscular Atrophy Awareness Month: Why Multidisciplinary Care Matters,” Sandeep Rana, MD, a neurologist specializing in neuromuscular disorders at Allegheny Health Network, discussed the multidisciplinary care model for spinal muscular atrophy (SMA) implemented in his center, in honor of SMA Awareness Month. He described a clinic structure that includes physical and occupational therapists, respiratory therapists, nutritionists, speech therapists, social workers, and collaboration with pulmonologists experienced in neuromuscular disease.Rana also outlined how the advent of disease-modifying therapies has transformed SMA from a largely fatal illness into a more manageable condition. He highlighted key advancements in therapeutics that have shifted priorities toward long-term wellness, including weight management, physical fitness, and emotional health. He noted persistent challenges in organizing and sustaining a specialized multidisciplinary team. Finally, he emphasized the importance of clinician awareness, early identification, and timely referral to tertiary centers, particularly as additional therapies may become available.Looking for more neuromuscular disorder discussions? Check out the NeurologyLive® Neuromuscular Disorders clinical focus page.Episode Breakdown: 1:25 – Professional background and clinic overview 2:55 – What an effective multidisciplinary SMA care team looks like 5:12 – How disease-modifying therapies have changed SMA care 6:28 – Neurology News Minute  9:27 – Organizational and procedural challenges in coordinating care 11:52 – Why raising awareness about SMA is important & advice to clinicians 13:45 – Key message about SMA today  The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts SL1009 Resubmission for PDCD, Sets December PDUFA Date FDA Advisory Committee Votes Against Deramiocel for DMD Cardiomyopathy FDA Grants RMAT Designation to Sasineprocel for Parkinson Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Multidisciplinary artist Kasim Hardaway reflects on the first year of “Take What You Need,” an interactive public art installation that pops up around Kansas City and invites people to pause and reflect on their lives.

What would you do if you were told you might only have two years to live?In this inspiring and deeply practical episode of Linda's Corner Podcast, I sit down with Glenn Sturm — bestselling author, astrophotographer, attorney, decorated military officer, and cancer survivor — to discuss multidisciplinary cancer care, emotional resilience, and what it really takes to fight for joy and quality of life after a devastating diagnosis.Glenn's life story is extraordinary. A graduate with honors from the University of Florida Levin College of Law and a decorated military officer with more than three decades of service, Glenn built a remarkable career as both a lawyer and leader. But in 2009, his life changed overnight when doctors discovered he had aggressive T-cell lymphoma.The diagnosis came completely out of the blue. Glenn didn't even realize he had been screened for cancer. Doctors told him there was no cure — only management — and estimated he might survive for only two years.That was seventeen years ago.Since then, Glenn has endured continuous chemotherapy and more than 55 surgeries, yet he continues to live a meaningful and fulfilling life. His perspective is powerful and refreshingly honest. Glenn openly shares what people are rarely told about surviving cancer: how important it is to protect your energy, maintain emotional resilience, and intentionally pursue hope and joy.One of the central themes of our conversation is the importance of multidisciplinary cancer care. Glenn explains why creating a collaborative treatment team can dramatically improve outcomes for cancer patients. He shared research suggesting that multidisciplinary approaches may reduce mortality rates anywhere from 14% to 90% compared to isolated or solo treatment strategies. His upcoming book, More Than Hope, explores these integrated cancer care approaches in greater depth.We also discuss the importance of quality of life during treatment. Glenn shares how finding the right medication dramatically improved his energy levels, which in turn improved both his daily life and longevity. As Glenn explains, improving quality of life is not just about comfort — it can also help people live longer. A true win-win.Beyond medicine, Glenn speaks candidly about the emotional side of survivorship and the daily decision to keep moving forward. His message is grounded in practical emotional survival and the belief that while we cannot control every circumstance, we can choose how we respond. As Glenn says, “Only you can stop you.”This episode is a powerful reminder that hope is not passive. It's something we actively build through connection, resilience, strategy, and purpose.You can learn more about Glenn Sturm and his work at:Glenn Sturm Official WebsiteGlenn is the author of several bestselling books, including:Cancer Set Me FreeWarriors Hate WarSyzygiesThe Great American Eclipse of 2017More Than Hope (upcoming)If you or someone you love has been impacted by cancer, chronic illness, or difficult life challenges, this episode offers practical wisdom, encouragement, and a hopeful reminder that life can still hold meaning, joy, and purpose — even in the middle of hardship.Listen, Share, and SupportIf this episode resonated with you, please share it with someone who may need hope today.Be sure to subscribe, leave a rating and review, and help us spread more healing and inspiration to the world.Free Resource for HealingIf you're ready to release stress, calm your mind, and begin healing from within, visit:

Melānie Mendez Munden is a multidisciplinary artist whose work spans fashion, film, and the visual arts. Her creative practice is driven by a passion for storytelling and a desire to explore the connections between artistic disciplines, using a variety of mediums to bring her ideas and vision to life.Expanding her platform for meaningful conversations, Melānie is launching her new radio show, WOW: Women of Wisdom, on 88.7 Cove FM, airing Thursdays at 7:00 PM. The show celebrates the voices of women through authentic, inspiring conversations and stories rooted in truth, resilience, and lived experience.Each week, Melānie will interview remarkable women from all walks of life, including entrepreneurs, mothers, physicians, scientists, artists, and leaders in the wellness community, sharing their journeys, wisdom, and insights to empower and inspire listeners.Learn more @mekizokeikaikoa@coffee_withmelanie

Today I'm joined by Dr. Amy Abelar, founder of Acupuncture Practice Systems and the owner of a thriving multidisciplinary clinic with 24 employees. Amy has built an incredible practice over the past 18 years, and in this conversation she shares the journey from starting as a massage therapist to growing a large acupuncture business with systems, team members, and strong leadership.In this first part of our conversation, we talk about:What it really looked like to grow her practice, including while she was in acupuncture school (!)How creating systems became the key to scalingWhen she knew it was time to hire additional providersWhat marketing worked well for her in growing her practiceAn overlooked marketing strategy that can dramatically increase patient retention and referralsIf you've ever wondered how larger practices are built or how to help your current patients get more value from the care you already provide, I think you're going to get a lot out of this conversation.This is part one of a two-part interview with Dr. Amy Abelar, so be sure to come back next week for the second half.Mentioned in this Episode (Show Notes):Acupuncture Practice SystemsYouTube: @AcupuncturePracticeSystemsInstagram: @AcupuncturePracticeSystemsMarketing Breakthrough Audit with Michelle

What does the future hold for kidney stone management? In Part 3, David S. Goldfarb explores disparities in care, promising areas of research, and the move towards more personalised approaches to prevention and treatment. He also discusses the impact of climate change on kidney stone risk and shares why he remains optimistic about the future of kidney stone care. Timestamps: 00:46 – Global warming 02:23 – Emerging research/treatments 03:57 – Asymptomatic kidney stones 04:58 – Broad, empiric approach to treatment 08:29 – Occupation as a risk factor for kidney stones 09:56 – Multidisciplinary care 11:51 – Climate change 13:47 – Calcium and kidney stones

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/managing-rett-syndrome-building-a-multidisciplinary-care-approach/57133/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/clinical-pearls-in-rett-syndrome-management-practical-approaches-to-multidisciplinary-care/57132/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/managing-rett-syndrome-building-a-multidisciplinary-care-approach/57131/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

Master MASLD/MASH diagnosis and multidisciplinary care. Credit available for this activity expires: 07/07/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/diagnosing-and-managing-obesity-linked-liver-disease-2026a1000ki0?ecd=bdc_podcast_libsyn_mscpedu

Sabina Wantoch PhD is a researcher, facilitator, consultant, artist and animist. They are an Honorary Associate Professor at the Centre for Multidisciplinary & Intercultural Inquiry at University College London, a consultant in peer support for mental health with Imroc, and co-founder of The Mad Psychedelics Collaboratory. Their work centres around madness and its porous intersections with varieties of altered states, as well as entanglements between paradigms and conceptual structures. Our conversation covers intersubjectivity and shared perception, reducing the fear of madness, the reciprocal nature of mythos, the varieties of meaning and sense-making, and the importance of equanimity.Sabina then shares three symbols they've created; the Net, the Bog, and the Crossroads. Inspired by tarot, these accompany their PhD thesis and form part of Sabina's upcoming deck that represents the mad experience.Link to Sabina's research.

► Today I'm welcoming onto the Polymath PolyCast. Julie Lavergne who is a polymathic generalist, TEDx Speaker, and Host of The Generalist Advantage podcast!Kicking off season 8 strong!Links:https://8ballclarity.com/TEDxhttps://www.linkedin.com/in/julie-lavergne/Generalist Advantage PodcastMentioned:Polymathy PanelChapters00:00 From Corporate to Curiosity: A Journey of Transformation02:44 The Engineering Mindset: Problem Solving and Process05:36 The Art of Communication: Navigating Multiple Roles08:35 Curiosity as a Skill: Embracing the Unknown11:27 Travel and Growth: Expanding Horizons through Experience14:18 The Juggling Act: Balancing Multiple Interests17:12 Content Creation: The Pursuit of Passion and Challenge20:00 TEDx and Beyond: Sharing Messages and Personal Growth22:38 The Art of Conversation: Orchestrating Meaningful Dialogues27:36 Defining Polymathy: Generalist vs. Polymath30:41 Measuring Accomplishment: The Polymath's Journey32:58 The Multidisciplinary Spectrum: Understanding Expertise38:30 The Genesis of the Generalist Advantage Podcast49:25 8 Ball Clarity: Enhancing Decision-Making with AI▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬► Affiliates:Videos Repurposed with Opus Clip:https://www.opus.pro/?via=729b77Social Posts Automated with Nuelink:http://nuelink.com/?via=dustin▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬►

Rachel is joined by Jacob Boehme, an award-winning filmmaker, choreographer, and cultural leader. Jacob shares his journey from a troubled teenager in Melbourne's western suburbs to his studies, where he discovered the deep connections between traditional cultural practice and theatre. We also explore his acclaimed solo work Blood on the Dance Floor, which centres First Nations experiences of living with HIV. He closes after speaking about his current role leading the Mob+ program at Thorne Harbour Health's Positive Living Centre in Prahran. Chapters 00:00 - Show introduction and guest overview 01:52 - Early theatre and dance beginnings 05:54 - Cultural discovery and identity at NAISDA 08:22 - Multidisciplinary ceremony as theatre practice 11:45 - Founding Yirramboi Festival with self-determination 15:50 - Blood on the Dance Floor 20:21 - Introducing the Mob Plus program 26:03 - Hopes for the future of Mob+ All chapter timecodes are approximate. Want more Well Well Well? Check out our other JOY Podcasts for more on LGBTIQ+ health and wellbeing at joy.org.au/wellwellwell. If there's something you'd like us to explore on the show, send through ideas or questions at wellwellwell@joy.org.au Find out more about LGBTIQ+ services and events in Victoria and South Australia at thorneharbour.org. Produced by: Rachel Cook, Jack Crnjanin

Please visit answersincme.com/FAJ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nancy L. Kuntz, MD; Vanessa Battista, DNP, MBA, CPNP-PC, CHPPN, FPCN, FAAN; and Ethan Hilgert. In this activity, experts in the management of spinal muscular atrophy (SMA) discuss the diagnosis and treatment of late-onset SMA (type 3b, 4) in adults. Upon completion of this activity, participants should be better able to: Recognize clinical features that are suggestive of SMA in adults; Review the evidence for approved disease-modifying therapies in adult patients with SMA; and Apply strategies that address barriers to achieving optimal clinical outcomes in adults with SMA.

Please visit answersincme.com/MRQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alexandra K. Golant, MD; Peter Lio, MD, FAAD; and Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP. In this activity, experts in dermatology discuss the OX40L pathway and its potential role in the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Identify the rationale for targeting the OX40/OX40 ligand (OX40L) pathway in the treatment of moderate-to-severe atopic dermatitis (AD); Assess the evidence on efficacy outcomes and safety profiles of the emerging OX40/OX40L inhibitors in AD, including quality of life (QoL) impact; Integrate QoL assessments into shared decision-making with patients who have moderate or severe AD; and Outline strategies for enhancing the multidisciplinary management of moderate-to-severe AD.

Please visit answersincme.com/MRQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alexandra K. Golant, MD; Peter Lio, MD, FAAD; and Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP. In this activity, experts in dermatology discuss the OX40L pathway and its potential role in the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Identify the rationale for targeting the OX40/OX40 ligand (OX40L) pathway in the treatment of moderate-to-severe atopic dermatitis (AD); Assess the evidence on efficacy outcomes and safety profiles of the emerging OX40/OX40L inhibitors in AD, including quality of life (QoL) impact; Integrate QoL assessments into shared decision-making with patients who have moderate or severe AD; and Outline strategies for enhancing the multidisciplinary management of moderate-to-severe AD.

Please visit answersincme.com/MRQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alexandra K. Golant, MD; Peter Lio, MD, FAAD; and Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP. In this activity, experts in dermatology discuss the OX40L pathway and its potential role in the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Identify the rationale for targeting the OX40/OX40 ligand (OX40L) pathway in the treatment of moderate-to-severe atopic dermatitis (AD); Assess the evidence on efficacy outcomes and safety profiles of the emerging OX40/OX40L inhibitors in AD, including quality of life (QoL) impact; Integrate QoL assessments into shared decision-making with patients who have moderate or severe AD; and Outline strategies for enhancing the multidisciplinary management of moderate-to-severe AD.

This episode of The Behavioral View explores collaboration between behavior analysts, school psychologists, special education teachers, and other professionals serving students across educational and clinical settings. The panel discusses practical strategies for building rapport with school teams, coordinating assessment and intervention efforts, and aligning goals across disciplines to improve learner outcomes. To earn CEUs for listening, click here, log in or sign up, pay the CEU fee, + take the attendance verification quiz to generate your certificate! Don't forget to subscribe and follow and leave us a rating and review. Show Notes: References Snyder SM, Huber H, Hornsby T, Leventhal B. (2024). Overlapping Training and Roles: An Exploration of the State of Interprofessional Practice between Behavior Analysts and School Psychologists. Behavior Analysis in Practice, 17(3):880-892. doi: 10.1007/s40617-023-00904-y Baer, D. M., Wolf, M. M., & Risley, T. R. (1968). Some current dimensions of applied behavior analysis. Journal of Applied Behavior Analysis, 1(1), 91–97. Cooper, J. O., Heron, T. E., & Heward, W. L. (2020). Applied behavior analysis (3rd ed.). Pearson. Resources CentralReach Institute: https://centralreach.com CR Assessments (ABLLS-R, AFLS, AIM): https://centralreach.com National Association of School Psychologists (NASP): https://www.nasponline.org The Behavioral View Podcast School-Wide Positive Behavioral Interventions and Supports (PBIS): https://www.pbis.org Multi-Tiered System of Supports (MTSS) Center

In this episode of Hema Now, we speak with Cecilia Karlström about advances in rare and complex haematological disorders. She discusses the evolving understanding of platelet refractoriness and transfusion support, the challenges in diagnosing systemic mastocytosis, and how targeted therapies are reshaping outcomes in rare blood diseases. The conversation also explores the growing role of precision medicine, multidisciplinary care, and future priorities in haematology research.  Timestamps:     00:00 – Introduction     01:21 – Career inspiration in haematology origins   02:43 – Evolution of platelet refractoriness management   03:39 – Current state systemic mastocytosis care   05:03 – Diagnosing systemic mastocytosis challenges today   07;26 – Impact of targeted therapies mastocytosis   07:26 – Future precision medicine opportunities haematology   09:00 – Multidisciplinary care improving patient outcomes   10:25 – Improving equity rare disease access   11:43 – Exciting research areas haematological disorders   13:14 – Three wishes future haematology advances

Welcome to Art is Awesome, the show where we talk with an artist or art worker with a connection to the San Francisco Bay Area.  This week, Emily Wilson sits down with Julia Goodman, a San Francisco-based artist who makes paper and textiles, as well as paintings and sculptures. They meet on the campus of the California College of the Arts — the last art school in San Francisco, set to close at the end of the 2026–27 school year — where Julia has been teaching. Their conversation covers Julia's winding path to art, the meditative and cathartic labor of making paper from recycled fabrics, grief, and an ongoing audio archive project about astronomy and motherhood. About Artist Julia Goodman: Julia Goodman is an artist and educator working at the intersection of papermaking, textiles, sculpture, and painting. Her work is held in the collections of the National Museum of Women in the Arts (NMWA), DePaul Art Museum, Recology San Francisco, and Google. Unimaginable Units of Time marks her first solo museum exhibition, presented at the San Luis Obispo Museum of Art. Recent group exhibitions include NMWA, Contemporary Jewish Museum, San Jose Museum of Art, DePaul Art Museum, Poetry Foundation, and Berkeley Art Center. Her residencies include JB Blunk Residency, Recology SF, Creativity Explored, Salina Art Center, The Space Program SF, and The Eames Institute. She is a recipient of the 2020 Women to Watch Award from the San Francisco chapter of NMWA. She is a longtime resident of the San Francisco Bay Area and started making paper in 2003 with a kitchen blender and old window screens. Visit Julia's  Website:  JAGoodman.com Follow Julia on Instagram:  @JuliaAnneGoodman Learn more about Julia's Wrenching News Workshops HERE. -- About Podcast Host Emily Wilson: Emily a writer in San Francisco, with work in outlets including Hyperallergic, Artforum, 48 Hills, the Daily Beast, California Magazine, Latino USA, and Women's Media Center. She often writes about the arts. For years, she taught adults getting their high school diplomas at City College of San Francisco. Follow Emily on Instagram: @PureEWil Follow Art Is Awesome on Instagram: @ArtIsAwesome_Podcast -- CREDITS: Art Is Awesome is Hosted, Created & Executive Produced by Emily Wilson.  Theme Music "Loopster" Courtesy of Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 4.0 License The Podcast is Co-Produced, Developed & Edited by Charlene Goto of @GoToProductions.  For more info, visit Go-ToProductions.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Please visit answersincme.com/860/IME_2025_00013162-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Toby Maher, MB, MSc, PhD, FRCP; and Justin Oldham, MD, MS. In this activity, experts explore advances in ILD care, including personalized, multidisciplinary approaches to integrate novel antifibrotic therapy and enhance patient engagement. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel antifibrotic therapy in interstitial lung disease (ILD); Apply the latest clinical data on novel antifibrotic therapy to therapeutic decision-making in ILD; and Outline multidisciplinary strategies to enhance the care of patients with ILD who are receiving antifibrotic therapies.

This episode of Lung Cancer Considered provide a preview of the upcoming IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea this September. Key topics covered include WCLC26 highlights - Multidisciplinary, WCLC26 deadlines and information about Seoul. Guests: Myung-Ju Ahn, MD, PhD Distinguished Professor Section of Hematology-Oncology, Department of Medicine Hanyang University Medical Center, Hanyang University School of Medicine Seoul, Republic of Korea Vincent Wentao Fang, MD Professor, Department of Thoracic Surgery Shanghai East Hospital Tongji University Medical School Jiraporn Setakornnukul, MD, PhD Radiation Oncologist, Associate Professor Division of Radiation Oncology Department of Radiology Faculty of Medicine, Siriraj Hospital Mahidol University Bangkok, Thailand Yasushi Yatabe, MD, PhD Chief, Department of Diagnostic Pathology, National Cancer Center Hospital Chief, Division of Molecular Pathology, National Cancer Center Research Institute National Cancer Center Japan

In this episode of Better Edge, Transplant Hepatologist Laura Lulik, MD moderates a panel discussion about the Northwestern Medicine Liver Transplant Tumor Clinic. The conversation covers advances in imaging, systemic therapies and innovative procedures, as well as the clinic's multidisciplinary approach.The panel includes: • Daniel Borja, MD, transplant surgeon• Aparna Kalyan, MD, medical oncologist • Robert Lewandowski, MD, interventional radiologist• Amira Borhani, MD, abdominal radiologist

Multidisciplinary astrophysicist, inventor, award-winning author, and journalist Hakeem Oluseyi joins Tavis in studio to discuss his newest book, “Why Do We Exist? The Nine Realms Of The Universe That Make You Possible,” and more.Become a supporter of this podcast: https://www.spreaker.com/podcast/tavis-smiley--6286410/support.

CardioNerds (Dr. Billy-Joe Mullinax, Dr. Dinu Balanescu, and Dr. Jane Ehret) discuss risk stratification in acute pulmonary embolism with Dr. Stavros Konstantinides, Chair of the 2019 ESC Pulmonary Embolism Guidelines. Using a real-world case, this episode explores how modern PE care has moved beyond “massive” and “submassive” labels toward a dynamic, physiology-based approach. The discussion highlights the limitations of static risk scores, the importance of right ventricular dysfunction and biomarkers, and why normotension does not imply stability. Special emphasis is placed on intermediate-high risk PE, early identification of impending hemodynamic collapse, and the role of lactate, serial reassessment, and PERT teams in guiding escalation of care. Audio editing by CardioNerds intern, Joshua Khorsandi.The 2026 American multi-society PE guidelines were published after this episode was recorded. Dr. Dinu Balanescu and Dr. Billy-Joe Mullinax are Co-chairs for the CardioNerds PE Series, developed in collaboration with the PERT Consortium.   Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Pulmonary Embolism PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Stable blood pressure does not mean low risk in PEHypotension is a late finding. Patients may have severe RV failure, hypoxia, and tissue hypoperfusion while remaining normotensive — a key concept behind “normotensive shock.” Risk stratification in PE must be dynamic, not staticLegacy scores like PESI and Bova provide a snapshot and predict 30-day mortality, but they do not capture short-term trajectory or impending hemodynamic collapse. Intermediate-high risk PE is a dangerous and heterogeneous groupPatients with RV dysfunction, positive biomarkers, tachycardia, hypoxemia, and elevated lactate may have in-hospital mortality approaching 15%, rivaling STEMI. Lactate is a critical but underutilized marker in PEElevated lactate reflects tissue hypoxia and early circulatory failure and may identify patients at risk for collapse before blood pressure declines. PERT enables physiology-driven, patient-centered PE carePERT teams operationalize continuous reassessment, integrate imaging, labs, and clinical trajectory, and allow timely escalation — shifting PE management from rigid categories to real-time decision-making. Notes Drafted by Dr. Jane Ehret. 1. What is the contemporary framework for risk stratification in acute pulmonary embolism? Modern PE risk stratification prioritizes hemodynamics and right ventricular (RV) function rather than clot burden. The 2019 ESC Guidelines classify PE into high risk, intermediate risk (low vs high), and low risk, based on: Hemodynamic status, RV dysfunction on imaging, and Cardiac biomarkers. This framework emphasizes early mortality risk but requires clinical context to guide escalation decisions. 2. Why is normotension insufficient to define “stability” in PE? Blood pressure is a late marker of circulatory failure in PE. Patients can maintain normal BP through Tachycardia, Increased sympathetic tone, and RV compensation. Many patients with preserved BP may already have shock physiology, including hypoxemia, elevated lactate, and RV failure — sometimes referred to as “normotensive shock.” 3. How should intermediate-risk PE be conceptualized clinically? Intermediate-risk PE is heterogeneous, ranging from patients who do well on anticoagulation to those who deteriorate rapidly. Intermediate-high risk PE is defined by RV dysfunction on imaging and positive cardiac biomarkers. Clinical features such as tachycardia, increasing oxygen requirement, and elevated lactate identify patients at highest risk within this group. 4. What are the strengths and limitations of commonly used PE risk scores? Legacy scores are useful for initial risk categorization but are static and limited in predicting short-term deterioration. Most scores were developed to predict mortality or complications at fixed time points rather than dynamic clinical trajectory. 5. What are the commonly used risk scores and clinical tools in PE, and what is each designed to predict? ESC Risk Stratification Algorithm: Identifies high-risk PE by hemodynamics. Uses PESI or sPESI in normotensive patients to distinguish low-risk from non–low-risk PE. Uses RV dysfunction and biomarkers to differentiate intermediate-low from intermediate-high risk. Forms the basis of many institutional PE pathways. PESI and sPESI: Validated to predict 30-day mortality. Widely used to identify low-risk patients appropriate for outpatient management. Heavily influenced by age and comorbidities. Bova Score: Predicts 30-day PE-related complications in normotensive patients. Composite PE Shock Score (CPES): Predicts normotensive shock in hemodynamically stable PE patients. Pulmonary Embolism Progression (PEP) Score: Predicts progression from intermediate-risk to high-risk PE within 72 hours of diagnosis. PE Short-term Clinical Outcomes Risk Estimation (PE-SCORE): Predicts clinical deterioration or death within 5 days of PE diagnosis. Hestia Criteria: Identifies low-risk PE patients safe for outpatient treatment. Wells' Criteria and Revised Geneva Score: Determine pretest probability for diagnostic triage. PERC Score: Rules out PE in very low-risk patients. 6. What is the role of biomarkers in PE risk stratification? Troponin and natriuretic peptides reflect RV myocardial injury and strain. Current guidelines treat biomarkers as binary (positive vs negative), despite risk being continuous. Biomarkers are most helpful for: Initial risk classification. They are less useful for: Short-interval monitoring and Detecting rapid clinical deterioration. 7. Why is lactate an important physiologic marker in PE? Lactate reflects global tissue hypoxia and impaired perfusion. Elevated lactate may identify patients with: Early circulatory failure and Increased risk of imminent hemodynamic collapse. Lactate is not currently included in ESC risk algorithms but may add important prognostic information in intermediate-risk patients. 8. How does trajectory influence decision-making in PE management? Risk stratification should be viewed as a dynamic process, not a one-time label. Worsening clinical trajectory may include: Rising heart rate, Increasing oxygen needs, Rising lactate, and Progressive RV dysfunction. Serial reassessment is essential for timely escalation of care. 9. What role do Pulmonary Embolism Response Teams (PERT) play in risk stratification? PERT facilitates: Multidisciplinary decision-making and Integration of imaging, biomarkers, and clinical physiology. PERT is most valuable for: Intermediate-risk and high-risk PE and Patients with complex comorbidities or uncertain trajectory. PERT enables a shift from category-based to physiology-driven PE care. References 1. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019;54(3):1901647. Published 2019 Oct 9. doi:10.1183/13993003.01647-2019 2. Leidi A, Bex S, Righini M, Berner A, Grosgurin O, Marti C. Risk Stratification in Patients with Acute Pulmonary Embolism: Current Evidence and Perspectives. J Clin Med. 2022;11(9):2533. Published 2022 Apr 30. doi:10.3390/jcm11092533 3. Choi WH, Kwon SU, Jwa YJ, et al. The pulmonary embolism severity index in predicting the prognosis of patients with pulmonary embolism. Korean J Intern Med. 2009;24(2):123-127. doi:10.3904/kjim.2009.24.2.123 4. Jiménez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170(15):1383-1389. doi:10.1001/archinternmed.2010.199 5. Chen X, Shao X, Zhang Y, et al. Assessment of the Bova score for risk stratification of acute normotensive pulmonary embolism: A systematic review and meta-analysis. Thromb Res. 2020;193:99-106. doi:10.1016/j.thromres.2020.05.047 6. Zhang RS, Yuriditsky E, Zhang P, et al. Composite Pulmonary Embolism Shock Score and Risk of Adverse Outcomes in Patients With Pulmonary Embolism. Circ Cardiovasc Interv. 2024;17(8):e014088. doi:10.1161/CIRCINTERVENTIONS.124.014088 7. Zhang RS, Alam U, Sharp ASP, et al. Validating the Composite Pulmonary Embolism Shock Score for Predicting Normotensive Shock in Intermediate-Risk Pulmonary Embolism. Circ Cardiovasc Interv. 2024;17(2):e013399. doi:10.1161/CIRCINTERVENTIONS.123.013399 8. Ehret J, Wakefield D, Badlam J, Antkowiak M, Erdreich B. Development of the Pulmonary Embolism Progression (PEP) score for predicting short-term clinical deterioration in intermediate-risk pulmonary embolism: a single-center retrospective study. J Thromb Thrombolysis. 2025;58(2):243-253. doi:10.1007/s11239-024-03051-5 9. Weekes AJ, Raper JD, Lupez K, et al. Development and validation of a prognostic tool: Pulmonary embolism short-term clinical outcomes risk estimation (PE-SCORE). PLoS One. 2021;16(11):e0260036. Published 2021 Nov 18. doi:10.1371/journal.pone.0260036 10. Zondag W, Hiddinga BI, Crobach MJ, et al. Hestia criteria can discriminate high- from low-risk patients with pulmonary embolism. Eur Respir J. 2013;41(3):588-592. doi:10.1183/09031936.00030412 11. Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med. 2001;135(2):98-107. doi:10.7326/0003-4819-135-2-200107170-00010 12. Wolf SJ, McCubbin TR, Feldhaus KM, Faragher JP, Adcock DM. Prospective validation of Wells Criteria in the evaluation of patients with suspected pulmonary embolism. Ann Emerg Med. 2004;44(5):503-510. doi:10.1016/j.annemergmed.2004.04.002 13. Le Gal G, Righini M, Roy PM, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med. 2006;144(3):165-171. doi:10.7326/0003-4819-144-3-200602070-00004 14. Kline JA, Mitchell AM, Kabrhel C, Richman PB, Courtney DM. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. J Thromb Haemost. 2004;2(8):1247-1255. doi:10.1111/j.1538-7836.2004.00790.x 15. Kline JA, Courtney DM, Kabrhel C, et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost. 2008;6(5):772-780. doi:10.1111/j.1538-7836.2008.02944.x

In this episode of Precision and Progress: Radiotherapy in Oncology, hosts Hirsch Matani, MD, and Elizabeth Zhang-Velten, MD, PhD, welcomed Binh T. Ngo, MD, to discuss the evolving role of radiation, systemic therapy, and multidisciplinary care for patients with melanoma and other skin cancers.Dr Matani is a clinical assistant professor of radiation oncology at the Keck School of Medicine of the University of Southern California (USC) and a radiation oncologist at the USC Norris Comprehensive Cancer Center. Dr Zhang-Velten is a radiation oncologist and a clinical assistant professor with Keck Medicine of USC. Dr Ngo is an assistant professor of dermatology at Keck Medicine of USC.In their discussion, Drs Matani, Zhang-Velten, and Ngo broke down how surgical approaches, radiation, and systemic therapy all play roles in the treatment of patients with skin cancer. Dr Ngo highlighted key prevention strategies that patients should be advised on, along with recommended follow-ups for patients who are at higher risk or those who underwent prior solid organ or hematologic transplants.The trio also discussed how the use of radiation for patients with skin cancer varies from techniques used for patients with tumors located within deeper organs, and they also highlighted how radiotherapy approaches could be applied for patients with tumors that would be difficult to surgically resect.

In today's episode, we spoke with Anthony Chi, MD, a staff pathologist; Monica Peravali, MD, a medical oncologist; and Archana Jadhav, MD, a medical oncologist, all faculty at the Mid-Atlantic Permanente Medical Group in Maryland. In our exclusive interview, Drs Chi, Peravali, and Jadhav discussed the practical advantages and clinical implications of implementing in-house next-generation sequencing (NGS) testing for patients with non–small cell lung cancer (NSCLC). The conversation focused on how internal molecular testing platforms can improve turnaround times, optimize tissue stewardship, reduce costs, and enhance quality control across the diagnostic and treatment continuums.Chi explained that performing NGS internally eliminates delays associated with specimen transportation and external laboratory accessioning, significantly shortening turnaround times. He also highlighted Kaiser Permanente's decision to implement a molecular platform distinct from those commonly used by outside vendors, allowing for reduced tissue input requirements and faster processing times. According to Chi, internal testing also gives pathology teams greater oversight of specimen use, enabling more strategic tissue conservation for future immunohistochemical (IHC) staining, repeat molecular analyses, or additional biomarker testing.The panel emphasized the importance of close coordination between pathology and oncology teams in maximizing tissue adequacy, particularly in small biopsies and cytology specimens. Chi described educational initiatives implemented within pathology departments to encourage judicious use of IHC stains and preserve tissue for downstream molecular testing. He also outlined specimen-handling workflows in which tissue is divided into separate cassettes to prioritize molecular analysis and still supporting diagnostic evaluation.Jadhav discussed the oncologist's role in ensuring adequate tissue acquisition, emphasizing proactive communication with pathologists and interventional radiologists. She noted that when clinicians anticipate limited tissue yield, such as in pleural fluid cytology specimens, they often promptly arrange additional biopsies to avoid delays in treatment initiation and ensure comprehensive genomic profiling can be completed efficiently.The discussion also addressed optimal timing for comprehensive genomic profiling in NSCLC. Peravali explained that Kaiser Permanente routinely performs NGS across all disease stages, including early-stage disease, due to increasing use of neoadjuvant chemoimmunotherapy approaches and the need to identify actionable biomarkers that may influence treatment selection. Although in-house testing serves as the primary platform, she noted that send-out testing remains important in select situations, including cancers of unknown primary origin, clinical trial enrollment, and discordant or clinically suspicious cases requiring additional confirmation.As molecular reports become increasingly complex, the panel highlighted the importance of interpreting co-mutations, variants of unknown significance, and emerging biomarkers within a broader clinical context. Peravali explained that although variants without current therapeutic relevance may not immediately affect treatment decisions, repeat biopsies and serial NGS at disease progression can reveal newly actionable alterations as therapeutic options evolve.Chi further emphasized the growing importance of newly approved biomarkers, including HER2 and c-MET alterations, in NSCLC. He described how pathology teams actively monitor FDA approvals and National Comprehensive Cancer Network (NCCN) guideline updates to identify new therapeutic opportunities for previously profiled patients. In some cases, archived tumor specimens are revisited for additional IHC testing when emerging therapies become clinically relevant.The conversation also highlighted the value of multidisciplinary collaboration and tumor board discussions in complex diagnostic scenarios. The speakers described how integrated molecular analysis can help distinguish separate primary lung tumors from metastatic disease, resolve diagnostically challenging cases involving uncommon metastatic presentations, and support more confident staging and treatment decisions.Finally, the panel underscored that successful implementation of precision oncology workflows depends on seamless collaboration among pulmonologists, pathologists, oncologists, interventional radiologists, and molecular laboratories. Early test ordering, centralized communication systems, and multidisciplinary case review were identified as key components of efficient, patient-centered care that can accelerate diagnosis and improve treatment planning for patients with lung cancer.

In this episode of Head and Neck Innovations, Edward Doyle, MD, and Varun Kshettry, MD, join host Paul Bryson, MD, to discuss the diagnosis and management of cerebrospinal fluid (CSF) leaks and encephaloceles. They explore common presentations, advances in imaging and diagnostic testing, and collaborative surgical approaches for skull base repair. The conversation also highlights the growing recognition of idiopathic intracranial hypertension as an underlying cause of spontaneous CSF leaks, as well as emerging treatment strategies including venous sinus stenting, weight management, and GLP-1 receptor agonists.

Multidisciplinary artist Maxi Glamour has shared their storytelling prowess through songwriting, drag and queer-friendly events by way of their Faeded series. Recently, they have completed “Faeded: The Opera” which premieres June 5 at the Contemporary Art Museum in partnership with the Pulitzer Arts Foundation. Glamour gives us a peek into their motivations to write their first opera, the evolution of Faeded over the years and their take on how “queerness” transcends sexual orientation.

In this episode, Ronjon Paul, MD, Orthopedic Spine Surgeon, Endeavor Health Medical Group, discusses developing multidisciplinary spine programs, leading within a large health system, and how AI is transforming patient care, clinical decision making, and physician workflows.

In this episode, CardioNerds Dr. Colin Blumenthal, Dr. Kelly Arps, and Dr. Yong Hao Yeo are joined by electrophysiology expert Dr. Bradley Knight to discuss atrial fibrillation (AF) management in challenging clinical scenarios. We explore arrhythmias in patients with pre-excitation syndromes, particularly Wolff-Parkinson-White (WPW) syndrome, and strategies for rhythm control. We also discuss AF management in pregnancy, adult congenital heart disease, and patients with tachycardia-bradycardia (tach-brady) syndrome. This episode provides essential insights into nuanced decision-making for the care of patients with complex arrhythmia profiles. Audio editing by CardioNerds academy intern, Grace Qiu. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Atrial Fibrillation PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! PEARLS AF in WPW is a true emergency—AV nodal blocking agents can be deadly. In patients with WPW syndrome, AF can rapidly conduct through the accessory pathway, risking ventricular fibrillation and sudden death. Avoid AV nodal blockers like beta-blockers and calcium channel blockers. Catheter ablation is the first-line rhythm control strategy in WPW. Catheter ablation carries a Class I recommendation and offers >90% success. If antiarrhythmic drugs are needed, sodium channel blockers like flecainide or propafenone are preferred in patients without structural heart disease. In pregnancy, protecting the mother is protecting the fetus. An unstable mother means an unstable fetus. Rate control is the first step in AF with rapid ventricular responses and electrical cardioversion is safe when needed. Multidisciplinary care is essential. AF in congenital heart disease is often outside the pulmonary veins. Surgical scars and chamber remodeling in ACHD patients often lead to AF from non-pulmonary vein foci. Electrogram-based mapping and targeted ablation strategies are essential to increase success rate of durable rhythm control. Tachy-brady syndrome may require pacing to unlock therapy. AF may cause atrial myopathy and sinus node dysfunction. These patients often require permanent pacing to allow safe use of rate-controlling medications like beta-blockers and to prevent syncope or chronotropic incompetence. Notes: Notes drafted by Dr. Yong Hao Yeo Why is atrial tachycardia in patients with WPW syndrome dangerous? Patients with WPW commonly present with supraventricular tachycardia (SVT) due to atrioventricular reentrant circuits, either orthodromic or antidromic. This SVT can degenerate into AF. In the absence of AV nodal as the governor between the atrium and ventricles, the accessory pathway may conduct impulses rapidly and frequently. This can lead to dangerously high ventricular rates, predisposing patients to ventricular fibrillation and sudden cardiac arrest. What are some strategies for rhythm control in patients with WPW and atrial tachycardia? Catheter ablation is the first-line therapy (Class I recommendation), with a success rate of over 90%. Ablation reduces the risk of sudden cardiac arrest, though some patients may remain prone to AF. If ablation is not feasible/ contraindicated, sodium channel blockers such as flecainide and propafenone are good options in patients without ischemia or structural heart disease (Class IIa recommendation). Amiodarone should be avoided because it has a long half-life, can accumulate in the system, and may delay definitive treatment with catheter ablation. AV nodal blocking agents like beta blockers and calcium channel blockers should be avoided, as they are less effective at controlling ventricular rate in WPW and can increase conduction over the accessory pathway. These agents can also exacerbate the risk of rapid ventricular rates during AF and worsen left ventricular function. What are some special considerations in managing AF in pregnant patients? The primary goal in managing cardiovascular disease during pregnancy is to protect the mother, as fetal outcomes depend on maternal well-being. Therefore, while caution is necessary, we should avoid undertreating pregnant patients with AF. In cases of AF with rapid ventricular response (RVR), rate control is usually the first-line strategy, with beta blockers preferred over digoxin or non-dihydropyridine calcium channel blockers. It is then reasonable to initially observe for spontaneous conversion in stable patients. Antiarrhythmic drugs (AADs) are generally avoided during the first trimester, but clinical judgment on a case-by-case basis is essential. Evidence for the safety of AADs in pregnancy is limited, often derived from their use in other conditions such as fetal SVT. Flecainide and sotalol are reasonable options for rhythm control (Class IIa recommendation). Electrical cardioversion is considered safe in pregnancy and should be utilized when indicated (Do not forget!). There is no pregnancy-specific thromboembolic risk stratification tool. CHA₂DS₂-VASc scoring and the presence of risk factors like mitral stenosis can help guide anticoagulation decisions, though the magnitude of thromboembolic risk during pregnancy remains unclear. Rate control agents are typically continued during delivery due to the increased physiologic stress of labor and delivery. Multidisciplinary care is crucial and should involve obstetrics, maternal-fetal medicine, cardiology, and electrophysiology specialists. What are some key considerations for AF management in patients with adult congenital heart disease (ACHD)? Patients with repaired congenital heart disease are at increased risk for arrhythmias due to two main factors: surgical scars that create arrhythmogenic foci and mechanical remodeling of the atria or ventricles resulting from the underlying disease. In these patients with structural heart disease, sodium channel blockers may not be ideal antiarrhythmic options. When selecting an antiarrhythmic drug, clinicians must consider the nature of structural or surgical impairments, such as right bundle branch block or prolonged QT interval. It is also essential to assess renal and hepatic function (often impaired in patients with ACHD) to ensure appropriate metabolism and clearance of antiarrhythmic medications. Electrogram-based ablation strategies (those leveraging artificial intelligence are developing!) may help identify effective ablation targets, which are often outside the pulmonary veins in patients with ACHD. These individualized approaches can improve ablation success rates in this complex patient population. What makes tachycardia-bradycardia (tach-brady) syndrome a unique challenge in arrhythmia management? Patients who present with both AF and bradycardia, especially with syncope, require a thoughtful diagnostic approach to identify the underlying rhythm disturbance. Extended cardiac monitoring, including event monitors or implantable loop recorders, can help capture intermittent arrhythmias and correlate them with symptoms. AF may lead to atrial myopathy, and since the sinus node resides within the atrium, this can result in sinus node dysfunction—a hallmark of tachy-brady syndrome. Following spontaneous conversion from AF to sinus rhythm, sinus node dysfunction may persist, leading to prolonged pauses or chronotropic incompetence. Management becomes more complex when beta-blockers are needed for AF with RVR, as they can exacerbate bradycardia. Permanent pacemaker implantation is often the next step to consider. Permanent pacemaker implantation is often considered to facilitate safe rate control in these cases. In younger patients, aggressive AF burden reduction may prevent atrial remodeling and the development of true atrial myopathy, potentially avoiding pacemaker implantation. References Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2023;149(1). doi:https://doi.org/10.1161/CIR.0000000000001193 ‌ Van IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2024;45(36). doi:https://doi.org/10.1093/eurheartj/ehae176 ‌ Joglar JA, Kapa S, Saarel EV, et al. 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy. Heart Rhythm. Published online May 1, 2023. doi:https://doi.org/10.1016/j.hrthm.2023.05.017 ‌ Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary. Journal of the American College of Cardiology. 2019;73(12):1494-1563. doi:https://doi.org/10.1016/j.jacc.2018.08.1028 ‌

They explain how occupational therapists, physical therapists, mental health professionals, pharmacists, and others can help you manage fatigue, pain, anxiety, daily routines, and life after diagnosis, while also sharing practical tips for advocating for referrals and support.  Episode at a glance: Why autoimmune arthritis care involves more than a rheumatologist and medications The surprising evidence behind occupational therapy (OT), physical therapy, and mental health support How OT can help with fatigue, pacing, daily routines, parenting, work, and mental health, not just hand pain Why anxiety, grief, and depression are common after diagnosis, and why getting support early matters Real-life strategies for managing fatigue and adapting daily tasks without “giving up” The hidden barriers that prevent patients from accessing multidisciplinary care Tips for advocating for referrals and building a supportive care team Cheryl and Eileen's personal experiences navigating rheumatoid arthritis, fatigue, anxiety, and self-management   Medical disclaimer:  All content found on Arthritis Life public channels (including Rheumer Has It) was created for generalized informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Episode Sponsors Rheum to THRIVE,  an online course and support program Cheryl created to help people with rheumatic disease go from overwhelmed, confused and alone to confident, supported and connected.  See all the details  and join the program or waitlist now! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.